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protocols under experimental conditions. Our laboratory is 
developing an in vivo radiobiology research program using the 
small animal radiotherapy research platform (SARRP, Xstrahl 
Life Sciences) as a central enabling technology to perform 
translational studies focussing on biologically optimised 
radiotherapy, nanoparticle theranostics and novel 
combination treatments. A major challenge now facing 
investigators is how to correctly apply the technology to 
accurately model clinical scenarios in relevant small animal 
models so that it can be exploited to its full potential in 
driving translational studies with outcomes likely to impact 
current standard of care in radiation oncology.  
An overview of the current state-of-the-art in preclinical 
radiotherapy will be presented including recent 
developments such as integration of bioluminescence 
imaging, preclinical 4-D CBCT and Monte Carlo based dose 
calculation methods. Examples of innovative preclinical 
studies will be highlighted along with experience from our 
own laboratory from commissioning to experimental design 
and important considerations for the successful execution of 
hypothesis-driven investigations using small animal 
radiotherapy.  
Despite certain challenges, small animal radiotherapy has 
much potential to bridge the translational gap between basic 
radiobiology and radiotherapy. As the technology develops 
and investigators gain experience as multidisciplinary 
scientists, pre-clinical studies that increasingly replicate the 
clinical scenario will drive new approaches in radiobiology 
that should ultimately translate to human health gains. 
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Although advances with in-vitro cancer cell culture models 
have occurred recently, in vivo tumor models are still crucial 
for the study of novel radiation treatments. This is 
particularly important for radiation combination approaches 
that target tumor cell non-autonomous anti-cancer pathways 
such as the tumor microenvironment or the immune system. 
In addition, more sophisticated animal studies with radiation 
are now possible with the advent of technologies that 
integrate treatment planning, imaging, and radiation delivery 
capabilities such as with the small-animal radiation platform 
(SARRP; Fig 1).  
 
 
Tumor xenograft models using human-derived tumor models 
implanted into immune-deficient mice are a mainstay of pre-
clinical testing and discovery. Although the majority of in 
vivo studies involve immunocompromised mice, such as 
athymic, severe combined immune-deficiency (SCID) or NOD-
SCID mice, these models are less ideal with radiation studies 
because some of these mice have mutations in DNA response 
and repair pathways. The abnormal DNA repair mechanisms 
in these mice limit the applicability of results with 
radiosensitizers given the integral role of DNA damage to the 
biologic effect of radiation therapy. Furthermore, anti-tumor 
effects of radiation may be mediated by the immune system. 
As a result of these limitations, genetically engineered mouse 
models (GEMMs) are becoming more widely used in 
preclinical studies with and without radiation. “Co-clinical 
trials” that use GEMMs that faithfully replicate the 
mutational events observed in human cancers to conduct 
preclinical trials that parallel ongoing human phase I/II 
clinical trials have shown great promise in cancer. This 
presentation will review published and on-going pre-clinical 
studies targeting both cancer cell autonomous and cancer 
cell non-autonomous pathways utilizing the SARRP with both 
xenograft tumor models and GEMMs at Johns Hopkins.  
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Clinical research faces many problems, of which the 
availability of pre-clinical models that predict the human 
situation is one of the most important. Pre-clinical tumour 
models are being used for decades in many cases with the 
assumption that they are predictive for what will later 
happen in humans. As such, the use of pre-clinical, mostly 
mouse, models may limit the exposure of inactive and or 
toxic treatments in patients. Although there is no doubt that 
pre-clinical models have been crucial to understand better 
molecular and other characteristics of carcinogenesis, growth 
and metastases and were the basis of many currently used 
cancer therapies, they still have considerable shortcomings. 
Classical mouse models use tumour cell lines that have been 
grown in vitro for many years and hence may have altered 
characteristics compared to de novo tumours. These tumour 
cells are then implanted subcutaneously in mice and tend to 
grow rapidly and thus do not mimic the much slower doubling 
times of most human cancers. This faster tumour growth may 
lead to a higher sensitivity for most chemotherapy drugs and 
hence erroneous conclusions. Moreover, in some situations, 
ectopic (out of the normal place) subcutaneously implanted 
tumours — still a standard methodology — may respond 
differently to treatment compared to tumours grown in an 
orthotopic site, i.e. in their organ or tissue of origin, such as 
breast cancers in mammary fat pads. The latter may 
correspond more to the human situation. Moreover, 
metastases frequently show other responses than primary 
tumours in patients, and it is only recently that these effects 
can be mimicked in genetically engineered mouse models. 
Tumour bearing mice are often treated with drugs at levels, 
or with pharmacokinetics, that are not relevant to humans. 
Furthermore, nearly all pre-clinical models have not used 
tumours that were pre-exposed to another therapy, whereas 
in many phase I and phase II clinical trials only patients that 
show tumour progression after one or more systemic 
treatments are included. With the huge interest in immune 
therapy, the use of humanised mice has gained even more 
attention than before. However, these models still face 
problems with remaining mouse innate immunity and weak 
human innate and adaptive immunity. Even the best models 
suffer from the development of wasting disease in highly 
engrafted humanized mice and poorly developed lymph nodes 
and germinal centres. It is also unclear if the cell trafficking 
resembles that of humans.At present, no single mouse models 
mimics perfectly the human situation. However, models that 
use injected tumour cells in the organ from which they were 
derived and which form metastases in organs that are similar 
to the human situation may be the most appropriate for they 
bear a micro-environment that resembles that of humans. 
